Zenarestat

Zenarestat
Names
	Preferred IUPAC name {3-[(4-Bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}acetic acid
Identifiers
CAS Number	112733-06-9 ;
3D model (JSmol)	Interactive image;
ChemSpider	5522;
IUPHAR/BPS	7418;
KEGG	D03807;
PubChem CID	5724;
UNII	180C9PJ8JT ;
CompTox Dashboard (EPA)	DTXSID0047296 ;
	InChI InChI=1S/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24) Key: SXONDGSPUVNZLO-UHFFFAOYSA-N; InChI=1/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24) Key: SXONDGSPUVNZLO-UHFFFAOYAB;
	SMILES C1=CC2=C(C=C1Cl)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O;
Properties
Chemical formula	C17H11BrClFN2O4
Molar mass	441.64 g/mol
Melting point	223 to 224 °C (433 to 435 °F; 496 to 497 K)
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Zenarestat (FK-366; FR-74366) is an aldose reductase inhibitor. It was investigated as a treatment of diabetic neuropathy and cataract, but its development was terminated.^[1]

References

M. Hashimoto et al., EP 218999; eidem, US 4734419 (1987, 1988 both to Fujisawa)
Inhibition kinetics and effect on sorbitol accumulation: S. Ao et al., Metabolism 40, 77 (1991)
Pharmacokinetics and metabolism in diabetic rats: Y. Tanaka et al., Drug Metab. Dispos. 21, 677 (1993)
M. Kanamaru et al., J. Clin. Pharmacol. 33, 1122 (1993).

^ "Zenarestat — AdisInsight". Adis Insight. Springer International Publishing AG. Retrieved 3 January 2016.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.